Daito Pharmaceutical Co.,Ltd.

TSE:4577 Stock Report

Market Cap: JP¥31.2b

Daito PharmaceuticalLtd Management

Management criteria checks 1/4

Daito PharmaceuticalLtd's CEO is Hiroshi Matsumori, appointed in Aug 2024, has a tenure of less than a year. directly owns 0.094% of the company’s shares, worth ¥29.22M. The average tenure of the management team and the board of directors is 2.1 years and 2.5 years respectively.

Key information

Hiroshi Matsumori

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.09%
Management average tenure2.1yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Daito PharmaceuticalLtd (TSE:4577) Is Due To Pay A Dividend Of ¥35.00

Feb 04
Daito PharmaceuticalLtd (TSE:4577) Is Due To Pay A Dividend Of ¥35.00

Daito PharmaceuticalLtd's (TSE:4577) Problems Go Beyond Weak Profit

Jan 18
Daito PharmaceuticalLtd's (TSE:4577) Problems Go Beyond Weak Profit

Daito PharmaceuticalLtd's (TSE:4577) Weak Earnings May Only Reveal A Part Of The Whole Picture

Jul 19
Daito PharmaceuticalLtd's (TSE:4577) Weak Earnings May Only Reveal A Part Of The Whole Picture

CEO

Hiroshi Matsumori (68 yo)

less than a year

Tenure

Hiroshi Matsumori is President at Daito Pharmaceutical Co. Ltd. since August 2024 and served as Vice President of Business Strategy & Head of Administrative Division since 2024 until August 2024 and served...

Leadership Team

NamePositionTenureCompensationOwnership
Hiroshi Matsumori
President & Representative Directorless than a yearno data0.094%
¥ 29.2m
Kazushige Hizume
Managing Exec. Officer6.5yrsno data0.14%
¥ 43.1m
Masuo Nomura
Directorno datano data0.0079%
¥ 2.5m
Hiroshi Kubota
Managing Exec. Officer2.1yrsno datano data
Yutaka Kuwashima
Managing Exec. Officer and GM of API Div. & Tokyo Branchno datano datano data
Yoji Nakamura
Exe.Off.no datano datano data
Yoshinori Nakajima
Exec. Off.no datano datano data
Eiichi Takata
Executive Officer and Head of Research & Development Divisionno datano datano data
Toru Ishida
Exec. Officerno datano datano data
Masahiko Mouri
Exec. Offi.no datano datano data
Norio Kishi
Executive Officerno datano datano data

2.1yrs

Average Tenure

66yo

Average Age

Experienced Management: 4577's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hiroshi Matsumori
President & Representative Director1.5yrsno data0.094%
¥ 29.2m
Kazushige Hizume
Managing Exec. Officer6.5yrsno data0.14%
¥ 43.1m
Masuo Nomura
Director1.5yrsno data0.0079%
¥ 2.5m
Toru Ishida
Exec. Officerless than a yearno datano data
Hitoshi Hori
Independent External Director9.5yrsno data0.12%
¥ 37.0m
Yasunobu Otsuga
Chairman of the Boardless than a yearno data2.39%
¥ 746.9m
Ichizo Yamamoto
Independent External Director9.5yrsno datano data
Atsushi Saino
Independent Outside Director7.5yrsno datano data
Kimiko Komatsu
Independent Outside Director2.5yrsno datano data

2.5yrs

Average Tenure

68yo

Average Age

Experienced Board: 4577's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 13:10
End of Day Share Price 2025/02/07 00:00
Earnings2024/11/30
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daito Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yukichi OkabeOkasan Securities Co. Ltd.
Takashi AkahaneTokai Tokyo Intelligence Laboratory Co., Ltd.
Masao YoshidaTokai Tokyo Intelligence Laboratory Co., Ltd.